News Lilly, PTC snap up bankrupt Sangamo's main assets Just a few weeks after filing for bankruptcy protection, Sangamo has found buyers for some of its key assets, raising up to $263.5m.
News PTC pulls file for Duchenne therapy on FDA feedback PTC Therapeutics has abandoned its latest attempt to secure FDA approval for Duchenne muscular dystrophy treatment Translarna.
News PTC stung by FDA decision not to approve rare disease drug It looks like PTC will have to carry out another trial of its drug for Friedreich ataxia before the FDA will consider approval.
News Germany will be first launch for PTC's phenylketonuria drug PTC Therapeutics' treatment for the rare disease PKU, Sephience, will launch in its first market next month after getting EU approval.
News PTC's Huntington study was positive. Why did its stock fall? In a potentially pivotal trial, PTC Therapeutics' therapy for Huntington's disease met its primary endpoint, but there are questions about the data.
News Italfarmaco closes on EU okay for Duchenne drug Italfarmaco's oral HDAC inhibitor Duvyzat has been recommended for approval in the EU as a treatment for Duchenne muscular dystrophy (DMD).
News ESC26: Isomab safety evidence on blood vessel growth for CAD Isomab has presented landmark safety data at ESC, clearing the path for next-generation therapies to promote blood vessel growth in CAD.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
